Clinical Trial Update: Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trials evaluating substitution of glucocorticoid for BDB-001 in ANCA-associated vasculitis have completed, with reported efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis

Drugs mentioned

• BDB-001
• Glucocorticoid (glucocorticoid)

Snippet

Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Conditions: ANCA-associated Vasculitis | Phase 1, Phase 2 | Status: COMPLETED